Biopharma financing totaled $12.4bn in 2019’s second quarter, a 31% decrease from Q1’s $17.96bn aggregate. Exactly one-third of the entire Q2 value was from follow-on public offerings, which brought in $4.1bn (see Exhibit 1). But unlike last quarter, the proportion of early-stage venture rounds and initial public offerings represented greater shares.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?